Ethylene Glycol
CAS 107-21-1
Ethylene Glycol (CAS 107-21-1) is a pharmaceutical compound with 1 bioactivity target and 16 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 13508.439999999999 nM | 5 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GLYCOL | 1314364 | SU | MTHSPL |
| ETHYLENE GLYCOL | 1314364 | SU | MTHSPL |
| ethylene glycol | 1314364 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ethylene Glycol used for in pharmaceutical contexts?
Ethylene Glycol (CAS 107-21-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ethylene Glycol?
Ethylene Glycol has 16 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cardio-respiratory arrest, Completed suicide, Death, Exposure to toxic agent, Suspected suicide. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ethylene Glycol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for GLYCOL with EU status "permitted".
What clinical phase is Ethylene Glycol in?
No phase 1-4 clinical development badge is rendered for Ethylene Glycol because the matched compound identifier rows do not contain a max-phase value.